Related Experiment Videos
Serotonin syndrome attributed to tramadol addition to paroxetine therapy
A C Egberts1, J ter Borgh, C C Brodie-Meijer
1Netherlands Pharmacovigilance Foundation, Tilburg, The Netherlands. A.C.G.Egberts@far.ruu.nl
International Clinical Psychopharmacology
|May 1, 1997
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Reasons for switching between antipsychotics in daily clinical practice.
Pharmacopsychiatry·2005
Bladder dysfunction during the use of tramadol.
Pharmacoepidemiology and drug safety·2004
Reduction in the therapeutic intensity of abortive migraine drug use during ACE inhibition therapy--a pilot study.
Pharmacoepidemiology and drug safety·2004
[Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy].
Nederlands tijdschrift voor geneeskunde·2003
Assessment of indicators for hospital drug formulary non-adherence.
European journal of clinical pharmacology·2002
Determinants of signal selection in a spontaneous reporting system for adverse drug reactions.
British journal of clinical pharmacology·2001
Use of risperidone in-situ microparticles in real world: patterns of prescription and dose selection in patients with psychotic disorders.
International clinical psychopharmacology·2026
Efficacy and safety of intramuscular and intravenous midazolam for acute agitation in emergency settings: a systematic review.
International clinical psychopharmacology·2026
Lithium and GLP-1-based therapies in bipolar disorder: an emerging pharmacovigilance signal and monitoring considerations.
International clinical psychopharmacology·2026
Effectiveness and safety of long-acting aripiprazole 960 mg: preliminary findings from a prospective real-world observational study.
International clinical psychopharmacology·2026
Critical reassessment of manic and psychotic episodes related to levetiracetam: a systematic review of published case reports.
International clinical psychopharmacology·2026
Methylphenidate treatment in adults with comorbid attention-deficit/hyperactivity disorder and borderline personality disorder: a prospective longitudinal study.
International clinical psychopharmacology·2026
Discontinuing extended-release buprenorphine: Participant experiences from a mixed-methods observational study.
Drug and alcohol dependence reports·2026